Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men
Open Access
- 23 May 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Abstract
Prostate cancer (PC) staging with conventional imaging often includes multiparametric magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest, abdomen, and pelvis, and whole-body bone scintigraphy. The recent development of highly sensitive and specific prostate specific membrane antigen (PSMA) positron emission tomography (PET) has suggested that prior imaging techniques may be insufficiently sensitive or specific, particularly when evaluating small pathologic lesions. As PSMA PET/CT is considered to be superior for multiple clinical indications, it is being deployed as the new multidisciplinary standard-of-care. Given this, we performed a cost-effectiveness analysis of [18F]DCFPyL PSMA PET/CT imaging in the evaluation of PC relative to conventional imaging and anti-3-[18F]FACBC (18F-Fluciclovine) PET/CT. We also conducted a single institution review of PSMA PET/CT scans performed primarily for research indications from January 2018 to October 2021. Our snapshot of this period of time in our catchment demonstrated that PSMA PET/CT imaging was disproportionately accessed by men of European ancestry (EA) and those residing in zip codes associated with a higher median household income. The cost-effectiveness analysis demonstrated that [18F]DCFPyL PET/CT should be considered as an alternative to anti-3-[18F]FACBC PET/CT and standard of care imaging for prostate cancer staging. [18F]DCFPyL PET/CT is a new imaging modality to evaluate PC patients with higher sensitivity and specificity in detecting disease than other prostate specific imaging studies. Despite this, access may be inequitable. This discrepancy will need to be addressed proactively as the distribution network of the radiotracer includes both academic and non-academic sites nationwide.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1-TR-002384)
This publication has 56 references indexed in Scilit:
- Use of Bone Scan During Initial Prostate Cancer Workup, Downstream Procedures, and Associated Medicare CostsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Impact of Age at Diagnosis on Prostate Cancer Treatment and SurvivalJournal of Clinical Oncology, 2011
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010
- ASTRO definition of biochemical failure is outperformed by alternativesNature Reviews Endocrinology, 2007
- Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapyUrologic Oncology: Seminars and Original Investigations, 2006
- Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancerUrology, 2006
- Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerUrology, 2006
- Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical ProstatectomyJAMA, 2005
- Patient Education for Informed Decision Making About Prostate Cancer Screening: A Randomized Controlled Trial with 1-Year Follow-UpThe Annals of Family Medicine, 2003
- Interpretation of cost-effectiveness analysesJournal of General Internal Medicine, 1998